Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Clinical trial NCT02303392 · COMPLETED

Trial details

NCT number: NCT02303392
Sponsor: Jennifer Woyach
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Prolymphocytic Leukemia Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia

Start date: 2015-06-09
Primary completion: 2022-04-18
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.